Rhythm Pharmaceuticals Reports Efficacy in New Obesity Drug Trial

Boston, Tuesday, 4 August 2026.
Preliminary Phase 2 data shows Rhythm Pharmaceuticals’ novel weekly injection achieved an 11.6% mean BMI reduction in 16 weeks, offering promising hope for hypothalamic obesity treatment.